SSR 180711 is a selective serotonin reuptake inhibitor (SSRI) of the fluoxetine class, primarily indicated for the treatment of major depressive disorder and obsessive-compulsive disorder. This compound… Read more
SSR 180711 is a selective serotonin reuptake inhibitor (SSRI) of the fluoxetine class, primarily indicated for the treatment of major depressive disorder and obsessive-compulsive disorder. This compound acts as a potent serotonin transporter (SERT) inhibitor, modulating synaptic serotonin levels to influence mood and anxiety regulation. To ensure compliance with regulatory standards and rigorous quality control, pharmaceutical laboratories require high-quality reference standards for analytical method development and validation. This category includes essential related compounds, such as degradation products, synthetic impurities, metabolites, and stable isotope labelled versions of the active pharmaceutical ingredient. These materials are critical for accurate impurity profiling and quantitative analysis throughout the drug manufacturing process, enabling precise identification and quantification of specific compounds in complex matrices during routine quality testing.